Skip to content

Royalty Pharma plc

RPRX· Nasdaqxbrl foundCIK 1802768

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -1.46%
Market cap
$39.56B
573.61M shares
Filings
643
$690.10M
Q3 2026+5.1% FY25 yoy
$144.68M
Q3 2026−10.2% FY25 yoy
$410.84M
Q3 2026+20.7% FY25 yoy
—
—
—
$0.32
Q3 2026−6.8% FY25 yoy
$513.66M
Q3 2026−33.4% FY25 yoy
$39.56B
58.8×
15.1×
4.0×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$68.96+77.00%+$30.00past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.38BFY 2025
$2.38B0FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$2,378,193,000reported
FY 20242024-12-31$2,263,576,000reported
FY 20232023-12-31$2,354,554,000reported
FY 20222022-12-31$2,237,215,000reported
FY 20212021-12-31$2,289,463,000reported
FY 20202020-12-31$2,122,353,000reported
FY 20192019-12-31$1,814,254,000reported
FY 20182018-12-31$1,794,894,000reported

Capital returns

Dividends and buybacks · FY2018 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$1.23B$1.23B————
FY2024—$229.65M$229.65M$0.84———
FY2023—$304.76M$304.76M$0.80———
FY2022—$0.00$0.00$0.76———
FY2021—$0.00$0.00$0.68———

Segments

Products
Revenue by Products, FY2018 to FY2025FY2018Income from financial royalty assets · FY2018 · $1.52BOther royalty income and revenues · FY2018 · $135.96MRevenue from intangible royalty assets · FY2018 · $134.12MFY2019Income from financial royalty assets · FY2019 · $1.65BOther royalty income and revenues · FY2019 · $19.64MRevenue from intangible royalty assets · FY2019 · $145.78MFY2020Income from financial royalty assets · FY2020 · $1.96BOther royalty income and revenues · FY2020 · $19.00MRevenue from intangible royalty assets · FY2020 · $143.38MFY2021Income from financial royalty assets · FY2021 · $2.07BOther royalty income and revenues · FY2021 · $53.13MRevenue from intangible royalty assets · FY2021 · $171.25MFY2022Income from financial royalty assets · FY2022 · $2.13BOther royalty income and revenues · FY2022 · $112.12MRevenue from intangible royalty assets · FY2022 · $37.48MFY2023Income from financial royalty assets · FY2023 · $2.20BOther royalty income and revenues · FY2023 · $156.80MRevenue from intangible royalty assets · FY2023 · $835.00KFY2024Income from financial royalty assets · FY2024 · $2.15BOther royalty income and revenues · FY2024 · $114.15MFY2025Income from financial royalty assets · FY2025 · $2.26BOther royalty income and revenues · FY2025 · $117.04M
LineFY2025ShareChange
Income from financial royalty assets$2.26B95%+5.2%
Other royalty income and revenues$117.04M4.9%+2.5%
Revenue from intangible royalty assets———
Total$2.38B

From the 10-K filed Feb 11, 2026RPRX

Pharmaceutical preparations

Royalty Pharma plc is the 26th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Royalty Pharma plc · CIK 1802768 · Engraved from SEC EDGAR